← Leaderboards
Thomas Scott Stroup
University Of North Carolina Chapel Hill
$20,597,752
Attributed
$25,797,687
Total exposure
8
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.8M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$34,297,427 · 9
By mechanism
R01$21,082,174 · 3
P50$12,356,185 · 4
K23$857,767 · 1
M01$1,301 · 1
Top collaborators
- David Kimhy5 shared
- Ragy Ramsis Girgis3 shared
Most similar at University Of North Carolina Chapel Hill
Same institution · by research overlap
- Lars Fredrik Jarskog$5,613,556
Others in their field
Top investigators on “Schizophrenia”
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$104,668,216
- Raquel E Gur · University Of Pennsylvania$60,189,770
- Mark J Daly · Broad Institute, Inc.$48,989,393
- John M Kane · Long Island Jewish Medical Center$45,235,871
- Carrie E Bearden · University Of California Los Angeles$42,025,230
- Scott W Woods · Yale University$41,221,536
Research focus
SchizophreniaEffectivenessPilot ProjectsTrainingPharmaceutical PreparationsEnsureBaseResearch PersonnelFundingResourcesSiteRandomizedClinical ResearchPersonalized InterventionMental HealthLongevityInnovationAntipsychotic AgentsNew YorkFosteringSamplingPersonsRegimenFuture
Grant awards (37)
1/7 Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial$1,289,413
R01 · FY2025 · MH
Optimizing and Personalizing interventions for schizophrenia Across the Lifespan (OPAL)$2,090,847
P50 · FY2023 · MH · contact PI
OPAL Center Administrative Core$879,855
P50 · FY2023 · MH · contact PI
1/7 Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial$1,282,144
R01 · FY2022 · MH
1/7 Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial$1,432,665
R01 · FY2021 · MH
OPTIMIZING AND PERSONALIZING INTERVENTIONS FOR SCHIZOPHRENIA ACROSS THE LIFESPAN (OPAL)$1,031,393
P50 · FY2021 · MH · contact PI
Administrative Core$451,724
P50 · FY2021 · MH · contact PI
Using mHealth to optimize pharmacotherapy regimens$160,849
P50 · FY2021 · MH · contact PI
Improving Cognition via Exercise in Schizophrenia$1,430,563
R01 · FY2020 · MH
OPTIMIZING AND PERSONALIZING INTERVENTIONS FOR SCHIZOPHRENIA ACROSS THE LIFESPAN (OPAL)$1,273,862
P50 · FY2020 · MH · contact PI
Administrative Core$306,053
P50 · FY2020 · MH · contact PI
Using mHealth to optimize pharmacotherapy regimens$166,521
P50 · FY2020 · MH · contact PI
Improving Cognition via Exercise in Schizophrenia$1,546,220
R01 · FY2019 · MH
OPTIMIZING AND PERSONALIZING INTERVENTIONS FOR SCHIZOPHRENIA ACROSS THE LIFESPAN (OPAL)$1,344,163
P50 · FY2019 · MH · contact PI
Administrative Core$478,966
P50 · FY2019 · MH · contact PI
OPTIMIZING AND PERSONALIZING INTERVENTIONS FOR SCHIZOPHRENIA ACROSS THE LIFESPAN (OPAL)$380,552
P50 · FY2019 · MH · contact PI
SUicide Reduction In Schizophrenia via Exercise (SUnRISE)$326,326
R01 · FY2019 · MH
OPTIMIZING AND PERSONALIZING INTERVENTIONS FOR SCHIZOPHRENIA ACROSS THE LIFESPAN (OPAL)$278,509
P50 · FY2019 · MH · contact PI
Administrative Core$278,505
P50 · FY2019 · MH · contact PI
Using mHealth to optimize pharmacotherapy regimens$151,950
P50 · FY2019 · MH · contact PI
Using mHealth to optimize pharmacotherapy regimens$1
P50 · FY2019 · MH · contact PI
OPTIMIZING AND PERSONALIZING INTERVENTIONS FOR SCHIZOPHRENIA ACROSS THE LIFESPAN (OPAL)$2,100,414
P50 · FY2018 · MH · contact PI
Improving Cognition via Exercise in Schizophrenia$1,536,619
R01 · FY2018 · MH
Administrative Core$913,466
P50 · FY2018 · MH · contact PI
Using mHealth to optimize pharmacotherapy regimens$68,555
P50 · FY2018 · MH · contact PI
Improving Cognition via Exercise in Schizophrenia$1,555,921
R01 · FY2017 · MH
2/2-A Comparison of Long-Acting Injectable Medications for Schizophrenia -ACLAIMS$743,259
R01 · FY2013 · MH · contact PI
2/2-A Comparison of Long-Acting Injectable Medications for Schizophrenia -ACLAIMS$2,380,698
R01 · FY2012 · MH · contact PI
2/2-A Comparison of Long-Acting Injectable Medications for Schizophrenia -ACLAIMS$2,997,389
R01 · FY2011 · MH · contact PI
2/2-A Comparison of Long-Acting Injectable Medications for Schizophrenia -ACLAIMS$3,008,160
R01 · FY2010 · MH · contact PI
2/2-A Comparison of Long-Acting Injectable Medications for Schizophrenia -ACLAIMS$1,552,797
R01 · FY2009 · MH · contact PI
CLINICAL MANAGEMENT OF METABOLIC PROBLEMS IN PATIENTS WITH SCHIZOPHRENIA:SW$1,301
M01 · FY2008 · RR · contact PI
Addressing Challenges in Schizophrenia Research$171,974
K23 · FY2007 · MH · contact PI
Addressing Challenges in Schizophrenia Research$171,514
K23 · FY2006 · MH · contact PI
Addressing Challenges in Schizophrenia Research$171,709
K23 · FY2005 · MH
Addressing Challenges in Schizophrenia Research$170,432
K23 · FY2004 · MH
Addressing Challenges in Schizophrenia Research$172,138
K23 · FY2003 · MH